AI can design proteins faster than labs can test them. LenioBio and Twist want to fix that bottleneck
AI can design proteins fast. Biology still sets the pace. LenioBio and Twist Bioscience are targeting drug discovery’s validation gap.
What the Invenra B-Body licensing deal changes for Twist Bioscience and antibody discovery services
Twist Bioscience licenses Invenra’s bispecific antibody platform. Find out how this reshapes biologics discovery infrastructure and industry dynamics.